Cempra has two antibiotic candidates, solithromycin (CEM-101) and TAKSTA™ (CEM-102, sodium fusidate), in clinical trials. Both target the growing problem of antimicrobial resistance.
Solithromycin is a next-generation macrolide, the first fluorok...查看全文
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-11-03 AccNo: 0001193125-17-333062 Size: 733 KBItem 1.01: Entry into a Material Definitive AgreementItem 2.01: Completion of Acquisition or Disposition of AssetsItem 2.03: Creation of a Direct Financial Obligation or an Obl...
$Cempra, Inc.(CEMP)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-02 AccNo: 0001564590-17-021211 Size: 4 MB 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-11-01 AccNo: 0001193125-17-329400 Size: 92 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-11-01 AccNo: 0001193125-17-329396 Size: 92 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-10-31 AccNo: 0001193125-17-326084 Size: 59 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-10-31 AccNo: 0001193125-17-326083 Size: 59 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-10-31 AccNo: 0001193125-17-326084 Size: 59 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-10-31 AccNo: 0001193125-17-326083 Size: 59 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Cempra, Inc.(CEMP)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2017-10-31 AccNo: 0001193125-17-326084 Size: 59 KB 网页链接
$Cempra, Inc.(CEMP)$ 8-K - Current report Filed: 2017-10-31 AccNo: 0001193125-17-326083 Size: 59 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接